{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:04:23Z","timestamp":1793963063997,"version":"4.8.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"f. hoffmann-la roche\/genentech, inc."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Limited information is available regarding real-world treatment patterns and their effectiveness and safety in patients with locally advanced basal cell carcinoma, including patients not typically represented in clinical trials. The purpose of the current study was to describe how clinicians diagnose and treat locally advanced basal cell carcinoma in the United States.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This prospective, multicenter, observational registry study included patients with newly diagnosed, Hedgehog pathway inhibitor\u2013naive locally advanced basal cell carcinoma without basal cell carcinoma nevus syndrome (n = 433) treated at 75 US academic and community practices, including dermatology, Mohs surgery, and medical oncology sites. The main outcomes of this study were treatment patterns and associated effectiveness and safety for patients with locally advanced basal cell carcinoma in real-world settings.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Determination of locally advanced basal cell carcinoma was mainly based on lesion size (79.6% of patients), histopathology (54.3%), extent of involvement (49.0%), and location (46.2%). Within 90 days of determination of locally advanced disease, 115 patients (26.6%) received vismodegib, 251 (58.0%) received surgery\/other (non-vismodegib) treatment, and 67 (15.5%) had not yet received treatment (observation). Vismodegib-treated patients had a higher prevalence of high-risk clinical features predictive for locoregional recurrence than those with non-vismodegib treatment or observation. Clinical response rate was 85.1% with vismodegib and 94.9% with non-vismodegib treatment (primarily surgery). The most common adverse events with vismodegib were ageusia\/dysgeusia, muscle spasms, alopecia, and weight loss. Rates of cutaneous squamous cell cancers were comparable between vismodegib and non-vismodegib treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This prospective observational study offers insight on real-world practice, treatment selection, and outcomes for a nationally representative sample of US patients with locally advanced basal cell carcinoma. For patients with lesions that were not amenable to surgery, vismodegib treatment was associated with effectiveness and safety that was consistent with that observed in clinical trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0262151","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T18:42:50Z","timestamp":1642185770000},"page":"e0262151","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1323-3220","authenticated-orcid":true,"given":"Aleksandar","family":"Sekulic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragini","family":"Kudchadkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Guillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Lynn S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Guenthner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"issue":"3","key":"pone.0262151.ref001","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archdermatol.2010.19","article-title":"Incidence estimate of nonmelanoma skin cancer in the United States, 2006","volume":"146","author":"HW Rogers","year":"2010","journal-title":"Arch Dermatol"},{"issue":"5","key":"pone.0262151.ref002","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2010.06.028","article-title":"Delayed treatment and continued growth of nonmelanoma skin cancer","volume":"64","author":"M Alam","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"pone.0262151.ref003","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jid.2012.403","article-title":"Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"133","author":"M-M Chren","year":"2013","journal-title":"J Invest Dermatol"},{"key":"pone.0262151.ref004","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s13671-014-0069-y","article-title":"Advanced basal cell carcinoma: epidemiology and therapeutic innovations","volume":"3","author":"SV Mohan","year":"2014","journal-title":"Curr Dermatol Rep"},{"key":"pone.0262151.ref005","doi-asserted-by":"crossref","first-page":"650258","DOI":"10.1155\/2011\/650258","article-title":"Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease","volume":"2011","author":"D Goppner","year":"2011","journal-title":"J Skin Cancer"},{"issue":"4 Suppl","key":"pone.0262151.ref006","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.sder.2011.11.004","article-title":"Assessing current treatment options for patients with severe\/advanced basal cell carcinoma","volume":"30","author":"MA Weinstock","year":"2011","journal-title":"Semin Cutan Med Surg"},{"key":"pone.0262151.ref007","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11864-013-0233-9","article-title":"Systemic therapy for inoperable and metastatic basal cell cancer","volume":"14","author":"LA Fecher","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"pone.0262151.ref008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-3-32","article-title":"Nevoid basal cell carcinoma syndrome (Gorlin syndrome)","volume":"3","author":"L. Lo Muzio","year":"2008","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"pone.0262151.ref009","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ctrv.2010.12.002","article-title":"Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cancer","volume":"37","author":"AK Ganti","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"pone.0262151.ref010","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJM196005052621803","article-title":"Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome","volume":"262","author":"RJ Gorlin","year":"1960","journal-title":"N Engl J Med"},{"key":"pone.0262151.ref011","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"N Basset-Seguin","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"pone.0262151.ref012","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"17","author":"A Sekulic","year":"2017","journal-title":"BMC Cancer"},{"issue":"23","key":"pone.0262151.ref013","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"A Sekulic","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0262151.ref014","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial","volume":"16","author":"MR Migden","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0262151.ref015","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CCO.0b013e32835ff438","article-title":"Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway","volume":"25","author":"A Sekulic","year":"2013","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"pone.0262151.ref016","first-page":"528","article-title":"Defining locally advanced Basal cell carcinoma","volume":"13","author":"TJ Maly","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"pone.0262151.ref017","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/fon.14.281","article-title":"Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus","volume":"11","author":"K Peris","year":"2015","journal-title":"Future Oncol"},{"key":"pone.0262151.ref018","unstructured":"Berchick ER, Hood E, Barnett JC. Health insurance coverage in the United States: 2017 Washington, DC, USA: United States Census Bureau; 2018 [cited 1 Apr 2021]. https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2018\/demo\/p60-264.pdf"},{"key":"pone.0262151.ref019","unstructured":"National Institute of Mental Health. Statistics: Mental illness. Bethesda, MD, USA: National Institutes of Health; 2021 [updated Jan 2021; cited 1 Apr 2021]. https:\/\/www.nimh.nih.gov\/health\/statistics\/mental-illness.shtml"},{"key":"pone.0262151.ref020","unstructured":"National Institute of Mental Health. Statistics: any anxiety disorder. Bethesda, MD, USA: National Institutes of Health; 2021 [updated Jan 2021; cited 1 Apr 2021]. https:\/\/www.nimh.nih.gov\/health\/statistics\/any-anxiety-disorder.shtml"},{"issue":"3","key":"pone.0262151.ref021","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/alz.12328","article-title":"2021 Alzheimer\u2019s disease facts and figures","volume":"17","author":"Alzheimer\u2019s Association","year":"2021","journal-title":"Alzheimers Dement"},{"key":"pone.0262151.ref022","doi-asserted-by":"crossref","first-page":"53","DOI":"10.12703\/P7-53","article-title":"Advances in the management of basal cell carcinoma","volume":"7","author":"JM Lewin","year":"2015","journal-title":"F1000Prime Rep"},{"issue":"2","key":"pone.0262151.ref023","first-page":"167","article-title":"Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management","volume":"88","author":"AG Marzuka","year":"2015","journal-title":"Yale J Biol Med"},{"issue":"5","key":"pone.0262151.ref024","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/archdermatol.2011.109","article-title":"Recurrence after treatment of nonmelanoma skin cancer: a prospective cohort study","volume":"147","author":"M-M Chren","year":"2011","journal-title":"Arch Dermatol"},{"issue":"3","key":"pone.0262151.ref025","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jaad.2005.04.087","article-title":"Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up","volume":"53","author":"I Leibovitch","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"pone.0262151.ref026","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaad.2005.04.083","article-title":"Basal cell carcinoma treated with Mohs surgery in Australia I. Experience over 10 years","volume":"53","author":"I Leibovitch","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"pone.0262151.ref027","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(08)70260-2","article-title":"Surgical excision versus Mohs\u2019 micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years\u2019 follow-up","volume":"9","author":"K Mosterd","year":"2008","journal-title":"Lancet Oncol"},{"issue":"9447","key":"pone.0262151.ref028","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(04)17399-6","article-title":"Surgical excision vs Mohs\u2019 micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial","volume":"364","author":"NW Smeets","year":"2004","journal-title":"Lancet"},{"key":"pone.0262151.ref029","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE BCC study: 12-month update of efficacy and safety of vismodegib in advanced basal cell carcinoma","volume":"72","author":"A Sekulic","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"pone.0262151.ref030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1470-2045(15)70198-1","article-title":"Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial","volume":"16","author":"N Basset-Seguin","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"pone.0262151.ref031","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaad.2017.03.038","article-title":"Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib","volume":"77","author":"T Bhutani","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"pone.0262151.ref032","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma","volume":"152","author":"SV Mohan","year":"2016","journal-title":"JAMA Dermat"},{"issue":"3","key":"pone.0262151.ref033","first-page":"219","article-title":"Vismodegib as a neoadjuvant treatment to mohs surgery for aggressive Basal cell carcinoma","volume":"14","author":"J Alcalay","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"pone.0262151.ref034","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2014.05.020","article-title":"An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma","volume":"71","author":"MS Ally","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"pone.0262151.ref035","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jamadermatol.2013.30","article-title":"Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome","volume":"149","author":"AL Chang","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"17","key":"pone.0262151.ref036","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.ejca.2014.08.018","article-title":"Surgical excision versus Mohs\u2019 micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up","volume":"50","author":"E van Loo","year":"2014","journal-title":"Eur J Cancer"},{"issue":"8","key":"pone.0262151.ref037","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/aje\/kwi098","article-title":"Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial","volume":"161","author":"N Pandeya","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"4","key":"pone.0262151.ref038","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1590\/abd1806-4841.20142742","article-title":"Quality of life and self-esteem in patients submitted to surgical treatment of skin carcinomas: long-term results","volume":"89","author":"PC Maciel","year":"2014","journal-title":"An Bras Dermatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T18:43:12Z","timestamp":1642185792000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262151"}},"subtitle":[],"editor":[{"given":"Panagiotis","family":"Balermpas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0262151","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]}}}